The size of the Epigenetics Market in Europe is expected to grow at a CAGR of 13.2% and reach USD 307.66 million in 2025 from USD 165.51 million in 2020.
Factors driving this market growth include increased cancer incidence and prevalence, increased funding for medical R & D, and increased use of epigenetic in non-neoplastic diseases. According to the World Health Organization (WHO), there are more than 3.7 million new cancer cases, and 1.9 million people die each year. Cancer is the second leading cause of death and morbidity in Europe. Epigenetics is used to study changes in gene expression that can be used to diagnose disease. It represents a massive pool of cancer patients driving the epigenetic market.
Europe Epigenetics Market, with the discovery of epigenetic drugs, is presumed to show modest growth during the forecast period. Also, cancer epidemics and advances in technology in epigenetic research are foreseen to drive Europe Epigenetics Market growth. The untapped potential of emerging Europe Epigenetics Market is expected to provide a variety of opportunities for market expansion. Advances in the epigenetic industry are focusing on the detection of methylation markers associated with cancer development. For example, the Geometrics Epi proLung BL Reflex test helps diagnose lung cancer by determining methylation of the SHOX2 biomarker gene.
The prevalence of cancer is rising, and the Europe Epigenetics Market is anticipated to grow. However, factors such as increasing equipment costs are assumed to limit market growth, and the shortage of skilled technicians is suspected of hindering the Europe Epigenetics Market growth.
The European epigenetics market is somewhat competitive and consists of several key players. In terms of market share, several vital players currently dominate the market. With the growing demand for mobile healthcare and the development of ultrasound technology, some small businesses have entered the Europe Epigenetics Market and have a significant share. The intense competition from leading players can suppress the revenue portion of new entrants.
This research report has been segmented & sub-segmented into the following categories:
Based on the research area, the Oncology segment holds the highest share in the market. Still, the drug discovery segment is expected to grow at the highest CAGR during the Forecast Period.
Regionally, Europe is the second-largest market owing to the stable economy and presence of market leaders.
Notable companies in the Europe epigenetics market are Abcam plc., Illumina, Inc., QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif, Diagenode, Inc. and Zymo Research Corporation.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
22.214.171.124 DNA-Modifying Enzymes
126.96.36.199 Protein-Modifying Enzymes
188.8.131.52 RNA-Modifying Enzymes
5.1.3 Instruments & Consumables
184.108.40.206 Mass Spectrometers
220.127.116.11 Next-Generation Sequencers
18.104.22.168 Bisulfite Conversion KITS
22.214.171.124 Chip-Sequence KITS
126.96.36.199 RNA Sequencing KITS
188.8.131.52 Whole-Genome Amplification KITS
184.108.40.206 5-HMC and 5-MC Analysis KITS
220.127.116.11 Magnetic Beads
5.1.6 Y-o-Y Growth Analysis, By Product
5.1.7 Market Attractiveness Analysis, By Product
5.1.8 Market Share Analysis, By Product
5.2 Research Area
5.2.2 Developmental Biology
5.2.4 Drug Delivery
5.2.5 Y-o-Y Growth Analysis, By Research Area
5.2.6 Market Attractiveness Analysis, By Research Area
5.2.7 Market Share Analysis, By Research Area
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Research Area
6.1.4 Market Attractiveness Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Product
220.127.116.11 By Research Area
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Research Area
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abcam plc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Illumina, Inc.
8.3 QIAGEN N.V.
8.4 Merck & Co.
8.5 New England Biolabs, Inc.
8.6 Zymo Research Corporation
8.7 Sigma-Aldrich Corporation
8.8 Thermo Fisher Scientific, Inc.
8.9 Active Motif
8.10 Diagenode, Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures